Tafamidis meglumine
Tafamidis meglumine: 1 brand, 0 generics; first approved May 03, 2019; on patent until Dec 19, 2026.
Protected until Dec 19, 2026 (earliest listed patent expiry).
Brand (NDA) products
- VYNDAQELRLDFOLDRX PHARMSNDA 2119962019
Approved strengths under this FDA application. Strength Dosage form Route Status TE 20MG CAPSULE ORAL Discontinued -
Patent & exclusivity timeline
Marketing exclusivity
- ODE-237Orphan-drug exclusivity (7 years)
6 mo ago
Listed patents
| Patent | Expires | In | Type |
|---|---|---|---|
| 7214696 | in 2 mo | U-2524 | |
| 7214695 | in 2 mo | SubstanceProduct |
Approval history
All 1 application were approved in 2019.
Tafamidis meglumine: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Tafamidis meglumine
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo